Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA
Correspondence: Victoria P. Werth. Email: [email protected]
Conflicts of interest: V.P.W. has received grants from Amgen, Argenx, AstraZeneca, Biogen, BMS, Celgene, Corbus Pharmaceuticals, CSL Behring, Genentech, Gilead, Horizon, Janssen, Pfizer, q32 Bio, Regeneron, Syntimmune, Ventus and Viela; and has consulted for AbbVie, Akari, Amgen, Argenx, AstraZeneca, Bayer, Beacon Bioscience, Biogen, BMS, Cabaletta Bio, Calyx, Celgene, Corcept, Crisalis, CSL Behring, Cugene, EMD Sorona, Genentech, Gilead, GSK, Horizon, Incyte, Janssen, Kezar, Kyowa Kirin, Lilly, Medscape, Merck, Nektar, Octapharma, Pfizer, Principia, Regeneron, Rome Pharmaceuticals, Sanofi, UCB, Viela Bio. University of Pennsylvania owns the copyright for the CDASI.
Received October 02, 2024
Received in revised form January 03, 2025
Accepted January 03, 2025
Revised February 19, 2025
